Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the Storz Duolith SD1 is more effective than placebo for treatment of heel pain syndrome for patients who have failed conservative treatment with other therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factors Affecting Response to Extracorporeal Shock Wave Therapy in Plantar Fasciitis: A Cross-sectional Clinical Study

NCT07006389

Plantar Fasciitis Plantar Heel Pain

ENROLLING_BY_INVITATION

Efficacy of the Treatment of Plantar Orthoses With Extracorporeal Shock Wave Therapy in Plantar Fasciitis

NCT04461197

Fasciitis, Plantar, Chronic

COMPLETED NA

"Comparison of Shockwave Application on the Sole of the Foot Vs. the Back of the Leg in the Treatment of Plantar Fasciitis: a Clinical Trial."

NCT06589037

Plantar Fasciitis

NOT_YET_RECRUITING NA

Comparing Two Protocols of Shock Wave Therapy for Patients With Plantar Fasciitis

NCT06174142

Plantar Fasciitis

NOT_YET_RECRUITING NA

Foot Core Stabilization Exercises Vs. Shockwave Therapy for Pain, Strength, and Function in Plantar Fasciitis

NCT06890806

Plantar Fasciitis of Both Feet

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plantar Fasciitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Verum

Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.

The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals.

Group Type ACTIVE_COMPARATOR

Duolith SD1

Intervention Type DEVICE

Placebo / Sham

Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.

Group Type SHAM_COMPARATOR

Sham Duolith SD1

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duolith SD1

Intervention Type DEVICE

Sham Duolith SD1

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Extracorporeal shock wave therapy ESWT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than 18 years
* ability of subject or legal respondent to give written informed consent
* signed informed consent
* diagnosis of painful heel syndrome
* 6 months of unsuccessful conservative treatment
* washout from conservative treatment
* scores of 5 or greater on three VAS scales
* score of 3 or 4 on Roles and Maudsley Scale
* willingness to refrain from specified concomitant therapies
* willingness to keep subject diaries
* negative urine pregnancy test (if applicable) required use of contraception (if applicable)

Exclusion Criteria

* tendon rupture, neurological or vascular insufficiencies
* inflammation of lower and upper ankle
* history of rheumatic disease, collagen, or metabolic disorders
* history of hyperthyroidism
* active malignant disease with or without metastasis
* Paget disease or calcaneal fat pad atrophy
* osteomyelitis
* fracture of calcaneus
* immunosuppressive therapy
* long term (6 months or greater) treatment with corticosteroid
* insulin dependent diabetes, severe cardiac or respiratory disease
* coagulation disorder or therapy with anticoagulants or antiplatelet drugs
* bilateral painful heel
* planned treatment within 8 weeks of enrollment that may confound pain results
* less than required washout of other treatments
* previous surgery for painful heel
* previous unsuccessful treatment for painful heel with shock wave device
* history of allergy or hypersensitivity to local anesthetics
* significant abnormalities of hepatic function
* poor physical condition
* pregnant female
* active infection or history of chronic infection in treatment area
* history of peripheral neuropathy
* history of systemic inflammatory disease
* history of worker's compensation or litigation
* participation in study of investigational device within 30 days of selection or current active study participation
* in the opinion of the investigator, inappropriate for study inclusion
* unwilling to comply with study requirements
* implanted pacemaker, insulin pump, defibrillator, or neurostimulator
* implanted prosthetic device in area of treatment
* open wounds or skin rashes

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No